Related Experiment Videos
Primary colorectal lymphoma
C W Fan1, C R Changchien, J Y Wang
1Division of Colon and Rectal Surgery, Chang Gung Memorial Hospital, Taipei, Taiwan.
Diseases of the Colon and Rectum
|September 27, 2000
Summary
High-grade lymphoma is a significant adverse prognostic factor in colorectal lymphoma. Adjuvant chemotherapy improves survival, particularly for Stage II disease patients.
Area of Science:
- Oncology
- Gastroenterology
- Pathology
Background:
- Primary colorectal lymphoma is a rare malignancy.
- Understanding its clinical presentation and prognostic factors is crucial for effective management.
Purpose of the Study:
- To review the clinical presentation and characteristics of primary colorectal lymphoma.
- To analyze prognostic factors influencing survival.
- To assess the efficacy of adjuvant chemotherapy in treatment outcomes.
Main Methods:
- Retrospective analysis of 37 primary colorectal lymphoma cases diagnosed between 1980 and 1996.
- Data collected included patient demographics, clinical signs and symptoms, tumor site, histology grade, and treatment received.
- Statistical analysis focused on identifying prognostic factors and survival rates.
Main Results:
- Abdominal pain, mass, and weight loss were the most common symptoms; the cecum was the most frequent site.
- The majority of lymphomas (78%) were high-grade.
- Adjuvant chemotherapy was associated with improved survival, especially in Stage II disease patients (median survival 36 months vs. 24 months).
Conclusions:
- High-grade lymphoma histology is the sole significant adverse prognostic factor.
- Adjuvant chemotherapy significantly enhances survival for Stage II colorectal lymphoma.
- Diffuse large-cell lymphoma shows better survival than small noncleaved-cell type in Stage II high-grade lymphoma.